Patents by Inventor Hiroitsu Kawata
Hiroitsu Kawata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 4879119Abstract: A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.Type: GrantFiled: August 26, 1988Date of Patent: November 7, 1989Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4772590Abstract: An oily composition of aclarubicin or aclarubicin hydrochloride comprising aclarubicin or aclarubicin hydrochloride; at least one fatty acid selected from saturated medium chain fatty acids, unsaturated medium chain fatty acids and unsaturated long chain fatty acids; and at least one fats and oils selected from iodized oils and vegetable oils.Type: GrantFiled: June 27, 1986Date of Patent: September 20, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Shunji Hasumi, Akira Okada, Masayoshi Aruga, Toshimitsu Konno, Ken Iwai, Hiroshi Maeda
-
Patent number: 4765988Abstract: Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.Type: GrantFiled: May 5, 1987Date of Patent: August 23, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroshi Sugiura, Tomoh Itoh, Masayoshi Aruga, Hiroitsu Kawata
-
Patent number: 4758437Abstract: A spherical pellet like composition of nicardipine composed of small granular nuclei such as sugar particles coated with amorphous nicardipine or a salt thereof, a pH-dependent additive and a surface active agent. The spherical pellet like composition of nicardipine may have a further coating of a medicament permeating material as an outermost coating. The spherical pellet like composition may be mixed with the spherical pellet like composition coated with the medicament permeating material.Type: GrantFiled: February 11, 1987Date of Patent: July 19, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota
-
Patent number: 4724148Abstract: Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.Type: GrantFiled: November 14, 1986Date of Patent: February 9, 1988Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Takashi Sonobe, Hiroshi Sugiura, Tomoh Itoh, Masayoshi Aruga, Hiroitsu Kawata
-
Patent number: 4707376Abstract: A granular composition of difficultly digestible polysaccharides (dietary fiber) is composed of a combination of one or more difficultly digestible polysaccharides selected from polysaccharides derived from roots of the plant such as glucomannan, polysaccharides derived from fruits of plants such as pectin, polysaccharides derived from seaweeds such as galactomannan, carragheenin, alginic acid, etc., various kinds of celluloses, and various kinds of brans and one or more difficultly digestible polysaccharides selected from alginates, alginic acid esters, agar, carboxymethyl cellulose salts, and pulullan.The granular composition of this invention is useful as a dietary food or dietary food additive.Type: GrantFiled: November 21, 1985Date of Patent: November 17, 1987Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kenichi Muraoka, Yoichi Setoguchi, Tadamasa Kawase, Hiroitsu Kawata, Hisamoto Komatsu, Makoto Uchida
-
Patent number: 4685911Abstract: A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.Type: GrantFiled: February 8, 1985Date of Patent: August 11, 1987Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4673564Abstract: Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material in nicardipine, the composition may consist only of the amorphous nicardipine oType: GrantFiled: October 23, 1985Date of Patent: June 16, 1987Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone
-
Patent number: 4637930Abstract: A formulation is provided for the transdermal administration of nicardipine hydrochloride. The formulation is comprised of nicardipine hydrochloride dissolved or suspended in a mixed liquid composed of an urea and at least one compound selected from the group consisting of propylene glycol, a monohydric alcohol having 2 to 4 carbon atoms, lactic acid, thioglycol, a middle chain fatty acid glyceride and a sorbitan middle chain fatty acid ester compounded with a transdermal formulation base.Type: GrantFiled: January 31, 1985Date of Patent: January 20, 1987Assignee: Yamanouchi Pharmaceutical Co, Ltd.Inventors: Yutaka Konno, Hiroitsu Kawata, Masayoshi Aruga, Takashi Sonobe, Mitsuo Mitomi
-
Patent number: 4578391Abstract: An oily composition of an antitumor drug comprising at least one sparingly oil soluble or water-soluble antitumor drug, at least one fat or oil, and at least one solubilizing adjuvant in an oily vehicle selected from the group consisting of crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyethylene alkylether, and sucrose esters of fatty acids.Type: GrantFiled: January 13, 1983Date of Patent: March 25, 1986Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Tadayoshi Ohmura, Shunji Hasumi, Yutaka Konno, Masayoshi Aruga, Seiki Tashiro, Toshimitsu Konno, Ken Iwai
-
Patent number: 4412986Abstract: A novel nifedipine-containing solid pharmaceutical preparation composition comprising a mixture of nifedipine and at least one 1st(a) substance selected from polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; a mixture of nifedipine, at least one 1st(b) substance selected from polyvinyl pyrrolidone, urea, citric acid mannitol, succinic acid, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and amino acid, and at least one 2nd substance selected from a surface active agent, polyethylene glycol, propylene glycol, glycerol, a glycerol fatty acid ester and a vegetable oil; or a mixture of nifedipine, the 1st(b) substance, the 2nd substance and calcium lactate.The composition of this invention can increase the bioavailability of nifedipine and makes it possible to provide a nifedipine-containing pharmaceutical preparation which has small bulk and can be easily administered.Type: GrantFiled: April 16, 1981Date of Patent: November 1, 1983Assignee: Yamanouchi Pharmaceutical Co. Ltd.Inventors: Hiroitsu Kawata, Tadayoshi Ohmura, Katsuhiko Yano, Mikio Matsumura, Saburo Higuchi, Yoshiaki Soeishi
-
Patent number: 4404183Abstract: Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine oType: GrantFiled: July 29, 1982Date of Patent: September 13, 1983Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone
-
Patent number: 4380534Abstract: A solid microdose drug preparation containing a microdose drug such as formoterol fumarate or .beta.-methyldigoxin coated with wax.In the drug preparation, the stability and the content uniformity of the microdose drug have been improved.Type: GrantFiled: April 1, 1981Date of Patent: April 19, 1983Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Muneo Fukui, Yutaka Konno, Yukio Kubota, Masayoshi Aruga, Hiroitsu Kawata
-
Patent number: 4343789Abstract: Sustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine orType: GrantFiled: July 2, 1980Date of Patent: August 10, 1982Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Takashi Sonobe, Satoru Yoneya, Chiharu Sone
-
Patent number: 4258179Abstract: A novel coating agent for solid medicaments containing a hydrogel-like substance of a water-insoluble hydroxypropyl cellulose having 5-16% by weight of a hydroxypropoxy group or the dry powder of a hydrogel-like substance. By coating solid medicaments with the coating agent, solid medicaments having high impact resistance and showing very less aging can be provided advantageously in industry.Type: GrantFiled: December 20, 1978Date of Patent: March 24, 1981Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Hiroitsu Kawata, Tadayoshi Ohmura, Hiroyoshi Shiozawa, Munetaka Hattori
-
Patent number: 4092428Abstract: There is provided a process of preparing a prostaglandin E group-containing formulation by adding to a prostaglandin E group at least one additive selected from the group consisting of thiol compound, a water-soluble high molecular weight compound, and a water-soluble salt of deoxycholic acid and then subjecting the mixture to lyophilization.Type: GrantFiled: March 7, 1977Date of Patent: May 30, 1978Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masuo Murakami, Shigemi Kawahara, Hiroitsu Kawata, Kiyoshi Okazaki, Jun Sekino, Hidemi Shimizu
-
Patent number: 4036954Abstract: There is provided a process of preparing a prostaglandin E group-containing formulation by adding to a prostaglandin E group at least one additive selected from the group consisting of a thiol compound, a water soluble high molecular weight compound and a water-soluble salt of deoxycholic acid and then subjecting the mixture to lyophilization.Type: GrantFiled: October 21, 1974Date of Patent: July 19, 1977Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masuo Murakami, Shigemi Kawahara, Hiroitsu Kawata, Kiyoshi Okazaki, Jun Sekino, Hidemi Shimizu